ArticleClinical kidney journal2026
Remnant cholesterol and cardiovascular risk in maintenance haemodialysis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remnant cholesterol (remnant-C) has emerged as a marker of residual cardiovascular risk beyond low-density lipoprotein cholesterol (LDL-C) but data in haemodialysis populations remain limited. We investigated the association of remnant-C with cardiovascular and mortality outcomes in maintenance haemodialysis patients. Methods: This post-hoc analysis included 624 patients from the prospective RISCAVID cohort. Remnant-C was calculated as total cholesterol minus high-density lipoprotein cholesterol minus directly measured LDL-C. The primary endpoint was 3-point major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal ischaemic stroke. All-cause mortality was analysed as a secondary endpoint. Associations were assessed using multivariable Cox regression models. Results: During a median follow-up of 31 months, 328 patients experienced a 3-point MACE and 375 died. Remnant-C was independently associated with 3-point MACE after adjustment for age, sex, traditional cardiovascular risk factors, LDL-C, and statin therapy (HR 1.06 per 10 mg/dl increase, 95% CI 1.01-1.11). The association remained significant after additional adjustment for the Geriatric Nutritional Risk Index (GNRI) and normalized protein catabolic rate. Restricted cubic spline analysis showed a progressive increase in cardiovascular risk across increasing remnant-C concentrations without evidence of a nonlinear threshold effect. For all-cause mortality, neither remnant-C nor LDL-C retained prognostic significance after multivariable adjustment. Conversely, GNRI was independently associated with mortality risk, whereas it was not associated with cardiovascular events. Conclusion: In maintenance haemodialysis patients, remnant-C was independently associated with major cardiovascular events but not with all-cause mortality, whereas the GNRI was associated with mortality but not cardiovascular outcomes. These findings suggest distinct contributions of residual atherogenic risk and nutritional status to cardiovascular and survival outcomes in end-stage kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.